PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in?vitro and in?vivo model of anaplastic thyroid carcinoma

摘要

PARP inhibitors are mostly effective as anticancer drugs in association with DNA damaging agents. We have previously shown that the oncolytic adenovirus dl922-947 induces extensive DNA damage, therefore we hypothesized a synergistic antitumoral effect of